Compare IBCP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBCP | ARVN |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.4M | 658.2M |
| IPO Year | 2010 | 2018 |
| Metric | IBCP | ARVN |
|---|---|---|
| Price | $33.01 | $10.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $37.00 | $15.05 |
| AVG Volume (30 Days) | 121.2K | ★ 651.5K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | 3.48 | ★ 58.84 |
| EPS | ★ 3.27 | N/A |
| Revenue | $32,075,000.00 | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.98 | N/A |
| P/E Ratio | $10.30 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $29.63 | $5.90 |
| 52 Week High | $37.39 | $14.22 |
| Indicator | IBCP | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 49.58 |
| Support Level | $31.55 | $9.02 |
| Resistance Level | $33.47 | $12.43 |
| Average True Range (ATR) | 0.93 | 0.51 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 12.43 | 61.68 |
Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.